New research indicates that people who stop using new weight-loss injections like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who halt traditional lifestyle programs.
Findings released in a leading medical journal demonstrates that while obese individuals can lose about a fifth of their total mass while using the jabs, the weight comes back at an average rate of 0.8 kg per month once they quit.
"People buying these drugs must be aware of the danger of rapid rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
That rate of regain means a return to starting weight in about a year and a half.
Analyzing Therapies
The research, which examined 37 of trials involving thousands of participants, compared the results of GLP-1 agonists with other pills.
The team emphasize that individuals who lose weight through lifestyle changes alone generally experience a slower weight regain—around 100 grams monthly—once they finish.
Explaining the Quick Regain
Experts propose the way of the injections accounts for the amplified rebound.
These medications mimic a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Artificially providing GLP-1 levels several times higher than normal may cause the body to produce less of its endogenous hormone, and may also reduce sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Stopping of this medication leads to appetite is uncontrolled, making overeating a significant risk."
A Lifelong Disease?
Medical guidelines advise the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals contend that, due to the high risk of weight regain, the therapy might need to be ongoing.
This opinion is reinforced by pharmaceutical companies, who note that the results "underscore the chronic character of obesity," similar to managing diseases like hypertension.
User Testimonies
Users who have discontinued the jabs describe a intense return of cravings.
"I experienced a switch activating and you become starving," recalled one woman.
This challenge is worsened if patients have not established permanent lifestyle or habit modifications during treatment.
Significant Interest
Recent estimates show that millions of adults in the UK have used these injections in the last 12 months, with desire being substantial.
- Use is higher among women compared to males.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, experts emphasize that while these medications are powerful tools for weight loss, they are not a permanent cure and maintained weight loss hinges on ongoing lifestyle changes.
